Home
Regulatory UpdatesSep 19, 2026•1 min read

FDA Discontinues Trimethobenzamide Injection (ANDA 089094)

By the PharmaCountry team

The FDA has listed the injectable Trimethobenzamide Hydrochloride (product 001) from sponsor SoloPak as discontinued under ANDA 089094.

The FDA’s drug approval database shows that the injectable product Trimethobenzamide Hydrochloride, marketed under the brand name TRIMETHOBENZAMIDE HYDROCHLORIDE with product number 001, has a marketing status of "Discontinued" under application number ANDA089094. The sponsor for this product is SoloPak. The product is an injection dosage form containing 100 mg/mL of Trimethobenzamide Hydrochloride. No reference drug or reference standard is indicated. The discontinued status means the product is no longer marketed in the United States.

Compiled by the PharmaCountry team · Source: FDA.gov

More articles

View all insights